Literature DB >> 20023594

Bisphosphonates pathway.

Li Gong1, Russ B Altman, Teri E Klein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 20023594      PMCID： PMC3086066          DOI： 10.1097/FPC.0b013e328335729c

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  54 in total

Review 1.  Organic anion transport is the primary function of the SLC17/type I phosphate transporter family.

Authors:  Richard J Reimer; Robert H Edwards
Journal:  Pflugers Arch       Date:  2003-06-17       Impact factor: 3.657

2.  Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

Authors:  S P Luckman; D E Hughes; F P Coxon; R Graham; G Russell; M J Rogers
Journal:  J Bone Miner Res       Date:  1998-04       Impact factor: 6.741

3.  An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates.

Authors:  D Thiébaud; A Sauty; P Burckhardt; P Leuenberger; L Sitzler; J R Green; A Kandra; J Zieschang; P Ibarra de Palacios
Journal:  Calcif Tissue Int       Date:  1997-11       Impact factor: 4.333

4.  COLIA1 Sp1 polymorphism predicts response of femoral neck bone density to cyclical etidronate therapy.

Authors:  A M Qureshi; R J Herd; G M Blake; I Fogelman; S H Ralston
Journal:  Calcif Tissue Int       Date:  2002-02-19       Impact factor: 4.333

5.  Interaction of Alkyl/Arylphosphonates, phosphonocarboxylates and diphosphonates with different anion transport systems in the proximal renal tubule.

Authors:  K J Ullrich; G Rumrich; T R Burke; S P Shirazi-Beechey; H Lang
Journal:  J Pharmacol Exp Ther       Date:  1997-12       Impact factor: 4.030

6.  1-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase.

Authors:  D Amin; S A Cornell; M H Perrone; G E Bilder
Journal:  Arzneimittelforschung       Date:  1996-08

7.  Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy.

Authors:  A Sauty; M Pecherstorfer; I Zimmer-Roth; P Fioroni; L Juillerat; M Markert; H Ludwig; P Leuenberger; P Burckhardt; D Thiebaud
Journal:  Bone       Date:  1996-02       Impact factor: 4.398

8.  Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis.

Authors:  D Amin; S A Cornell; S K Gustafson; S J Needle; J W Ullrich; G E Bilder; M H Perrone
Journal:  J Lipid Res       Date:  1992-11       Impact factor: 5.922

9.  Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.

Authors:  F H Glorieux; N J Bishop; H Plotkin; G Chabot; G Lanoue; R Travers
Journal:  N Engl J Med       Date:  1998-10-01       Impact factor: 91.245

10.  The acute-phase response after bisphosphonate administration.

Authors:  S Adami; A K Bhalla; R Dorizzi; F Montesanti; S Rosini; G Salvagno; V Lo Cascio
Journal:  Calcif Tissue Int       Date:  1987-12       Impact factor: 4.333
View more
  19 in total

1.  May zoledronic acid have negative effects on cognition and muscle performance?

Authors:  Remzi Bahşi; Volkan Atmiş; Tuğba Turgut; Deniz Mut Sürmeli; Çağlar Coşarderelioğlu; Hande Selvi Öztorun; Ahmet Yalçin; Sevgi Aras; Murat Varli
Journal:  Ir J Med Sci       Date:  2019-08-19       Impact factor: 1.568

Review 2.  Biology, pathology, and therapeutic targeting of RAS.

Authors:  J Matthew Rhett; Imran Khan; John P O'Bryan
Journal:  Adv Cancer Res       Date:  2020-07-09       Impact factor: 6.242

3.  Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3.

Authors:  Paola Nicoletti; Vassiliki M Cartsos; Penelope K Palaska; Yufeng Shen; Aris Floratos; Athanasios I Zavras
Journal:  Oncologist       Date:  2012-01-20

4.  PharmGKB: the Pharmacogenomics Knowledge Base.

Authors:  Caroline F Thorn; Teri E Klein; Russ B Altman
Journal:  Methods Mol Biol       Date:  2013

Review 5.  Serotonergic Mechanisms Regulating the GI Tract: Experimental Evidence and Therapeutic Relevance.

Authors:  Natalie Terry; Kara Gross Margolis
Journal:  Handb Exp Pharmacol       Date:  2017

6.  High-level copy number gains of established and potential drug target genes in gastric cancer as a lead for treatment development and selection.

Authors:  Mariette Labots; Tineke E Buffart; Josien C Haan; Nicole C T van Grieken; Marianne Tijssen; Cornelis J H van de Velde; Heike I Grabsch; Bauke Ylstra; Beatriz Carvalho; Remond J A Fijneman; Henk M W Verheul; Gerrit A Meijer
Journal:  Cell Oncol (Dordr)       Date:  2013-12-31       Impact factor: 6.730

7.  A polymorphism at the translation start site of the vitamin D receptor gene is associated with the response to anti-osteoporotic therapy in postmenopausal women from southern Italy.

Authors:  Valeria Conti; Giusy Russomanno; Graziamaria Corbi; Giuseppe Toro; Vittorio Simeon; Walter Filippelli; Nicola Ferrara; Michela Grimaldi; Valeria D'Argenio; Nicola Maffulli; Amelia Filippelli
Journal:  Int J Mol Sci       Date:  2015-03-10       Impact factor: 5.923

8.  The effect of alendronate on proteome of hepatocellular carcinoma cell lines.

Authors:  Amber Ilyas; Zehra Hashim; Nadia Naeem; Kanwal Haneef; Shamshad Zarina
Journal:  Int J Proteomics       Date:  2014-02-06

9.  Zoledronic acid suppresses transforming growth factor-β-induced fibrogenesis by human gingival fibroblasts.

Authors:  Yuko Komatsu; Miho Ibi; Naoyuki Chosa; Seiko Kyakumoto; Masaharu Kamo; Toshiyuki Shibata; Yoshiki Sugiyama; Akira Ishisaki
Journal:  Int J Mol Med       Date:  2016-05-10       Impact factor: 4.101

10.  Smart, programmable and responsive injectable hydrogels for controlled release of cargo osteoporosis drugs.

Authors:  Konstantinos E Papathanasiou; Petri Turhanen; Stephan I Brückner; Eike Brunner; Konstantinos D Demadis
Journal:  Sci Rep       Date:  2017-07-06       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.